DOCS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Doximity Inc (DOCS) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has shown some positive price movement recently, the technical indicators, financial performance, and mixed analyst ratings suggest a cautious approach. The lack of strong trading signals and the absence of significant positive catalysts further support a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 39.445, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), suggesting a downtrend. The stock is trading near its first resistance level (R1: 25.816), which could limit further upside in the short term.
Piper Sandler highlighted the promising potential of Doximity's AI tool suite, DoxGPT, which could drive long-term growth. Analysts like Canaccord and Needham view the recent selloff as an overreaction, creating a potential buying opportunity.
The company's Q3 financials showed declining net income (-18.14% YoY) and EPS (-16.22% YoY), with gross margins also slightly down. Analysts have lowered price targets across the board, citing regulatory uncertainties and a weaker Q4 outlook. No recent news or significant trading trends from hedge funds, insiders, or Congress were observed.
In Q3 2026, revenue grew by 9.76% YoY to $185.05M, but net income dropped by 18.14% YoY to $61.56M. EPS also fell by 16.22% YoY to $0.31, and gross margin decreased slightly to 89.89%. These figures indicate some growth but also highlight profitability challenges.
Analyst ratings are mixed, with some firms (e.g., Piper Sandler, Canaccord) maintaining a positive outlook, while others (e.g., JPMorgan, BMO Capital) have downgraded price targets significantly. The consensus reflects cautious optimism but acknowledges near-term headwinds.
